Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

July/August 2019

Column

Editor's Page
Where We Are With Value Assessment in Oncology
08/19/2019
Winston Wong, PharmD, Editor-in-Chief
Value assessment in oncology is an emerging area of interest, as demonstrated by the multiple value assessment tools launched in the last 5 years to help stakeholders analyze the efficacy, tolerability, and...
Value assessment in oncology is an emerging area of interest, as demonstrated by the multiple value assessment tools launched in the last 5 years to help stakeholders analyze the efficacy, tolerability, and...
Value...
08/19/2019
Journal of Clinical Pathways
Editorial
Strategic Vision of the OCM 2.0 Alternative Payment Model
08/19/2019
JCP Editors
In June 2019, the Community Oncology Alliance (COA) announced a detailed alternative payment model (APM) that includes proposals for value-based contracts that would provide high-quality oncology care at a low cost....
In June 2019, the Community Oncology Alliance (COA) announced a detailed alternative payment model (APM) that includes proposals for value-based contracts that would provide high-quality oncology care at a low cost....
In...
08/19/2019
Journal of Clinical Pathways
PATIENT PERSPECTIVE
Can We Talk? Discussing What Matters With the People Who Matter
08/19/2019
Melissa Williams, MPH
Rebecca Kirch, JD
Alan Balch, PhD—Column Editor
Literature shows that patients feel better when they have the opportunity to express emotional concerns and their physicians respond empathically. When patients feel heard and understood, they are also better...
Literature shows that patients feel better when they have the opportunity to express emotional concerns and their physicians respond empathically. When patients feel heard and understood, they are also better...
...
08/19/2019
Journal of Clinical Pathways
Clinical Pathways GPS
Ramifications of “Medicare for All” and Implications for Clinical Pathways
08/19/2019
Matthew Pakizegee, PharmD, MS
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and...
As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and...
As the...
08/19/2019
Journal of Clinical Pathways
Pharma Insights
The Evolution of Value Frameworks and What Is Next
08/19/2019
Jeremy Schafer, PharmD, MBA
Larry Blandford, PharmD—Column Editor
Value assessment in oncology is an emerging area of interest. Multiple value frameworks have been launched in the past 5 years to help stakeholders analyze the cost-effectiveness, or affordability, of oncology...
Value assessment in oncology is an emerging area of interest. Multiple value frameworks have been launched in the past 5 years to help stakeholders analyze the cost-effectiveness, or affordability, of oncology...
Value...
08/19/2019
Journal of Clinical Pathways
Counterpoint
Incorporating Patient Perspectives and Transparency for Patient-Centered Value Assessment
08/19/2019
Tom Valuck, MD, JD
Matthew Castner, MHA
Enhanced integration of the patient’s voice in health care is the next step in the evolution of a patient-centered delivery system. To remain in line with this evolution, value assessment should incorporate the...
Enhanced integration of the patient’s voice in health care is the next step in the evolution of a patient-centered delivery system. To remain in line with this evolution, value assessment should incorporate the...
...
08/19/2019
Journal of Clinical Pathways
Viewpoint
The Value of a Transparent, Inclusive Assessment Tool in Health Care
08/19/2019
Surabhi Dangi-Garimella, PhD
The value conversation for a drug, especially from a patient’s perspective, extends well beyond merely drug cost. In addition to utilization of cost-effectiveness analyses, decision makers need access to all relevant...
The value conversation for a drug, especially from a patient’s perspective, extends well beyond merely drug cost. In addition to utilization of cost-effectiveness analyses, decision makers need access to all relevant...
The...
08/19/2019
Journal of Clinical Pathways

Department

Research in Review
Research in Review
08/19/2019
JCP Editors
ASCO Releases Framework for Including Research Biopsies in Clinical Trials The American Society of Clinical Oncology released an ethical framework for incorporating research biopsies in cancer clinical...
ASCO Releases Framework for Including Research Biopsies in Clinical Trials The American Society of Clinical Oncology released an ethical framework for incorporating research biopsies in cancer clinical...
ASCO...
08/19/2019
Journal of Clinical Pathways

Insights

Interview
Emerging Data Initiatives Using Real-World Evidence to Better Inform Oncology Care
08/19/2019
JCP Editors
Randomized clinical trials (RCTs) use a well-established methodology for gathering robust evidence of the safety and efficacy of medical interventions. They remain the “gold standard” of data for evaluating new...
Randomized clinical trials (RCTs) use a well-established methodology for gathering robust evidence of the safety and efficacy of medical interventions. They remain the “gold standard” of data for evaluating new...
...
08/19/2019
Journal of Clinical Pathways
Feature
Current State of Myelodysplastic Syndromes: Standard Treatment Practices and Therapeutic Advances
08/19/2019
Mark G Faber, DO
Elizabeth A Griffiths, MD
Swapna Thota, MD
Abstract: Patients with myelodysplastic syndromes (MDS) collectively have a high symptom burden and are also at risk of death from complications of cytopenias and acute myeloid leukemia. The goals of therapy for...
Abstract: Patients with myelodysplastic syndromes (MDS) collectively have a high symptom burden and are also at risk of death from complications of cytopenias and acute myeloid leukemia. The goals of therapy for...
...
08/19/2019
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Volume 5

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement